Twitter Inc predicts a shareholder vote on the $44 billion sale to Elon Musk could take place in early August as the company continues to work constructively to finalize the deal with the world's richest person, Twitter company executives said on Wednesday towards employees in social networks.
Musk's lawyers warned Twitter Monday that he could withdraw from the acquisition if the company doesn't provide the data it seeks on spam and fake accounts.
Twitter said it continues to share information with Musk. Part of that data is "firehose," a phrase that includes all of the platform's tweets, which are analyzed according to various parameters such as user devices or the profiles of the accounts posting the tweets, according to people familiar with the matter.
sells this data to social media surveillance companies as part of its licensing business, but plans to give it to Musk for free as part of its information sharing, the sources said. The fire hose does not contain any sensitive information, such as B. Twitter users' personal information that is not public or how often they check their accounts, the sources added.
Last month, Twitter CEO Parag Agrawal tweeted that he didn't think a count of fake and spam accounts could be done outside the company because it would require private information that Twitter can't share.
It was unclear how much sensitive information about its user base Twitter will share with Elon Musk
. The Washington Post first reported on the fire hose replacement.
A Musk spokesman did not immediately respond to a request for comment.
Twitter lead attorney Vijaya Gadde told a staff meeting that the company plans to hold a shareholder vote on the Musk deal in late July or early August.
During the internal meeting, the company's top executives said that Twitter is working to strengthen its defenses against fake accounts and accounts distributing cryptocurrency spam.Also Read: Is a cancer cure finally on the way? For the first time in history, the new medicine Dostarlimab cures all of the patients in a clinical trial